| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — |
| EBITDA Margin | — | — | — | — | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 3.84 | 0.83 | 2.31 | 7.64 | 24.69 | 68.15 | 5.83 | 22.81 | 0.23 | 5.74 |
| Quick Ratio | 3.84 | 0.83 | 2.31 | 7.64 | 24.69 | 68.15 | 5.83 | 22.81 | 0.23 | 5.74 |
| Debt / Equity | — | — | — | — | — | — | — | — | — | — |
| ROE | -203.83% | -1303.03% | -416.11% | -106.58% | -47.47% | -58.04% | -352.39% | -139.31% | -773.30% | -254.31% |
| ROA | -159.75% | -511.87% | -289.21% | -94.64% | -45.72% | -57.20% | -301.47% | -133.48% | -263.12% | -216.28% |
| Asset Turnover | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
| Book Value / Share | 8.54 | 0.40 | 5.42 | 0.46 | 0.88 | 0.87 | — | 0.64 | 0.04 | 0.15 |
Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The company's technologies deliver disease-fighting genes to address unmet needs in these patient populations. Its oncology program employs the systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to encapsulate gene-expressing plasmids targeting cancer cells. The lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is under evaluation in clinical trials for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), with programs receiving FDA Fast Track and Orphan Drug designations. For diabetes, Genprex advances GPX-002, utilizing an AAV vector to deliver Pdx1 and MafA genes to the pancreas; in Type 1 diabetes, it transforms alpha cells into insulin-producing beta-like cells that evade immune detection, while in Type 2, it rejuvenates exhausted beta cells. Recent efforts include licensing additional technologies for glioblastoma treatment and advancing diabetes research with non-viral delivery systems. Founded in 2009 and headquartered in Austin, Texas, Genprex collaborates with leading institutions to expand its gene therapy pipeline in oncology and endocrinology.